Emiliem, Inc is a private biotechnology company currently focused on all aspects of the drug discovery and development process. This includes understanding the molecular determinants of target modulation as it relates to the efficacy of therapeutics and to potential adverse drug reactions, and diagnostic markers for rare diseases and the computational aspects of predicting both positive and negative patient outcomes.